<DOC>
	<DOCNO>NCT00273702</DOCNO>
	<brief_summary>After complete screen evaluation , subject receive unblinded N-Acetyl Cysteine 600 mg/day 2 week . The dose raise 1200 mg/day visit 4 1800 mg/day visit 6 unless clinical improvement attain low dose ( clinical improvement assess investigator respect gamble thought , urge behavior ) . If clinically necessary modify schedule ( e.g. , side effect adequate response lower dose ) , dose raise slowly target dose reach . Subjects start psychotropic medication study may continue previously prescribe psychotropic medication stable dose 3 month prior study entry . Psychotherapy form ( include cognitive-behavioral therapy ) initiate study subject may continue current psychotherapy undergo therapy least three month prior study entry . Subjects evaluate PG-YBOCS , G-SAS , CGI , HAM-D , HAM-A Sheehan Disability Inventory screen visit remainder study . Medication side effect evaluate study visit . A tablet count keep dose medication take .</brief_summary>
	<brief_title>An Open-Label Study N-Acetyl Cysteine Pathological Gambling</brief_title>
	<detailed_description>Before begin N-Acetyl Cysteine , subject receive psychiatric , medical , family history evaluation well Structured Clinical Interview DSM-IV ( SCID-P ) Axis I disorder . At screen visit , patient also receive standard laboratory test ( include ÃŸ-HCG ) , physical examination . The following instrument complete screen visit periodically throughout study : 1 ) Yale-Brown Obsessive Compulsive Scale Modified Pathological Gambling ( PG-YBOCS ) , reliable valid semi-structured clinician-administered scale ass current severity PG ; 2 ) Gambling Symptom Assessment Scale ( G-SAS ) , reliable valid self-report measure gamble symptom ; 3 ) 17-item Hamilton Rating Scale Depression ( HAM-D ) ; 4 ) 17-item Hamilton Rating Scale Anxiety ( HAM-A ) ; 5 ) Clinical Global Impression scale ; 6 ) Sheehan Disability Inventory ; 7 ) Quality Life Inventory . Safety evaluation , include pulse blood pressure , assessment side effect do visit . After complete screen evaluation , subject receive unblinded N-Acetyl Cysteine 600 mg/day 2 week . The dose raise 1200 mg/day visit 4 1800 mg/day visit 6 unless clinical improvement attain low dose ( clinical improvement assess investigator respect gamble thought , urge behavior ) . If clinically necessary modify schedule ( e.g. , side effect adequate response lower dose ) , dose raise slowly target dose reach . Subjects start psychotropic medication study may continue previously prescribe psychotropic medication stable dose 3 month prior study entry . Psychotherapy form ( include cognitive-behavioral therapy ) initiate study subject may continue current psychotherapy undergo therapy least three month prior study entry . Subjects evaluate PG-YBOCS , G-SAS , CGI , HAM-D , HAM-A Sheehan Disability Inventory screen visit remainder study . Medication side effect evaluate study visit . A tablet count keep dose medication take .</detailed_description>
	<mesh_term>Gambling</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Men woman age 1865 Current DSMIV PG Unstable medical illness physical examination History seizures Myocardial infarction within 6 month Current pregnancy lactation , inadequate contraception woman childbearing potential Clinically significant suicidality Lifetime history DSMIV bipolar disorder type I , dementia , schizophrenia DSMIV psychotic disorder Current recent ( past 3 month ) DSMIV substance abuse dependence Illegal substance within 2 week study initiation Initiation psychotherapy behavior therapy mental health professional within 3 month prior study baseline Previous treatment NAcetyl Cysteine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Gambling</keyword>
	<keyword>Gambler</keyword>
	<keyword>Gamble</keyword>
	<keyword>Pathological</keyword>
</DOC>